Kraft Heinz Co vs Medtronic PLC — how do they compare? Kraft Heinz Co trades at $25.99 (market cap $30.66B), while Medtronic PLC trades at $83.21 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 3.5× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| KHC | MDT | |
|---|---|---|
Market Cap | $30.66B | $106.61B |
Sector | Consumer Staples | Health |
52-Week High | $28.94 | $105.35 |
52-Week Low | $21.21 | $73.75 |
Enterprise Value | $47.71B | $125.36B |
Dividend Yield | 6.19% | 3.46% |
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $26.05, up 0.66% today, with a bullish technical signal and recent earnings beats. The stock shows strong operating cash flow of $4.46B in 2025 but faces profitability challenges with a net income margin of -23.05%. Analysts are mixed, with 57% holding a neutral stance, while the company's reorganization aims to spur growth. The dividend yield remains attractive at approximately 6.4%, supported by solid cash generation.
Outlook: KHC offers value with a low P/B of 0.73 and high dividend, but risks include persistent net losses and high debt. The upcoming Q2 2026 earnings on August 5 will be critical for confirming turnaround progress. Investors should weigh the dividend stability against fundamental weaknesses in a competitive food sector.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →